Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 3Not yet recruiting 3Recruiting 2Completed 2Withdrawn 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Chemotherapy-Induced Thrombocytopenia 1

Interventions

pembrolizumab 437Carboplatin 322Nivolumab 292Cyclophosphamide 281Specimen Handling 271Magnetic Resonance Spectroscopy 257Cisplatin 253Paclitaxel 248Radiotherapy 229Gemcitabine 183Biopsy 182Dexamethasone 181durvalumab 168atezolizumab 151Rituximab 138Doxorubicin 135Lenalidomide 134Bevacizumab 133Docetaxel 131Ipilimumab 129Capecitabine 120Radiation 118Oxaliplatin 114Radiosurgery 113Pemetrexed 112Etoposide 111Fluorouracil 110venetoclax 106fludarabine 106Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × hetrombopag × Clear all
NCT05864014 2025-04-16

Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors.

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Active not recruiting
213 enrolled
Classical hematology

Chemotherapy-Induced Thrombocytopenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡